Abstract
Cardiovascular disease still remains the primary cause of death worldwide and obesity is becoming recognized as one of the most critical contributing risk factors. The increased prevalence of obesity casts a cloud over the global health and the whole societies and will still be burdened in the future. Therefore, prevention and therapy of obesity is a beneficial strategy for the prevention of chronic cardiovascular disease. Numerous studies have demonstrated that gut microbiota takes part in human health and disease including obesity. Traditional herbs hold great potential to improve people’s health and wellness, particularly in the area of chronic inflammatory diseases although the mechanisms of action remain poorly understood. Emerging explorations of gut microbiotaherb interactions provide a potential to revolutionize the way we view herbal therapeutics. This review summarizes the experimental studies performed on animals and humans regarding the gut microbiota-herb interactions targeting obesity. This review also discusses the opportunity of herbs with potent activities but low oral bioavailability conundrum for prevention and therapy for obesity and related cardiovascular disease.
Keywords: Obesity, cardiovascular disease, gut microbiota, oral availability conundrum, gut microbiota-herb interactions, microbiota availability.
Current Pharmaceutical Design
Title:Targeting Obesity for the Prevention of Chronic Cardiovascular Disease Through Gut Microbiota-Herb Interactions: An Opportunity for Traditional Herbs
Volume: 23 Issue: 8
Author(s): Feng Chen, Jun Jiang*, Dan-Dan Tian, Qi Wen, Yong-Hui Li, Jun-Qing Zhang, Chen Cheng and Tengfei Wang*
Affiliation:
- Hainan Medical College, 3 Xueyuan Road, Haikou 571199,China
- Department of Pharmacology, University of Tennessee Health Science Center, Memphis, TN 38163,United States
Keywords: Obesity, cardiovascular disease, gut microbiota, oral availability conundrum, gut microbiota-herb interactions, microbiota availability.
Abstract: Cardiovascular disease still remains the primary cause of death worldwide and obesity is becoming recognized as one of the most critical contributing risk factors. The increased prevalence of obesity casts a cloud over the global health and the whole societies and will still be burdened in the future. Therefore, prevention and therapy of obesity is a beneficial strategy for the prevention of chronic cardiovascular disease. Numerous studies have demonstrated that gut microbiota takes part in human health and disease including obesity. Traditional herbs hold great potential to improve people’s health and wellness, particularly in the area of chronic inflammatory diseases although the mechanisms of action remain poorly understood. Emerging explorations of gut microbiotaherb interactions provide a potential to revolutionize the way we view herbal therapeutics. This review summarizes the experimental studies performed on animals and humans regarding the gut microbiota-herb interactions targeting obesity. This review also discusses the opportunity of herbs with potent activities but low oral bioavailability conundrum for prevention and therapy for obesity and related cardiovascular disease.
Export Options
About this article
Cite this article as:
Chen Feng, Jiang Jun*, Tian Dan-Dan, Wen Qi, Li Yong-Hui, Zhang Jun-Qing, Cheng Chen and Wang Tengfei*, Targeting Obesity for the Prevention of Chronic Cardiovascular Disease Through Gut Microbiota-Herb Interactions: An Opportunity for Traditional Herbs, Current Pharmaceutical Design 2017; 23 (8) . https://dx.doi.org/10.2174/1381612822666161014115724
DOI https://dx.doi.org/10.2174/1381612822666161014115724 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Variations in Cytochrome P450 2C9 and 2C19: A Review
Current Pharmacogenomics and Personalized Medicine Female Infertility and Antioxidants
Current Women`s Health Reviews Pregnancy, Physical Activity, Functional Capacity and Adaptations to Exercise
Current Women`s Health Reviews Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Direct Interaction of Dietary Lipids Carried in Chylomicron Remnants with Cells of the Artery Wall: Implications for Atherosclerosis Development
Current Pharmaceutical Design Mesenchymal Stem Cells Induced In Vitro Generated Regulatory-T Cells: Potential Soldiers of Transplantation Biology
Current Biotechnology The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Ion Channels as Therapeutic Targets for Type 1 Diabetes Mellitus
Current Drug Targets Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Pharmacotherapy of Aortic Stenosis-Success or Failure?
Current Pharmaceutical Biotechnology Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Current Cancer Drug Targets Cellular Mechanisms of the Protective Effect of Polyphenols on the Neurovascular Unit in Strokes
Cardiovascular & Hematological Agents in Medicinal Chemistry The Anabolic Effects of GH / IGF System on Bone
Current Pharmaceutical Design Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews Identification of Novel Structurally Diverse Anaplastic Lymphoma Kinase Inhibitors Based on Pharmacophore Modeling, Virtual Screening and Molecular Docking
Combinatorial Chemistry & High Throughput Screening Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Current Pharmaceutical Design Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Current Neuropharmacology AMP-activated Protein Kinase as a Drug Target in Chronic Kidney Disease
Current Drug Targets A Brief Review of Blue- and Bilberries’ Potential to Curb Cardio-Metabolic Perturbations: Focus on Diabetes
Current Pharmaceutical Design